U.S. President Donald Trump has signed an executive order to expand access to in vitro fertilization (IVF), addressing declining birth rates in developed countries. With more couples delaying parenthood, the assisted reproductive technology (ART) market is booming.
 
Taiwan is emerging as a key player in reproductive medicine, with cutting-edge biotech companies driving innovation:
 

• Bonraybio (6955.TW) – A total solution for male infertility, improving sperm health and function
• iPreg – Advanced sperm sorting technology to enhance fertilization success
• Inti Labs – Non-invasive egg evaluation for higher implantation rates
• Jamon – Microfluidic chip technology simulating the oviduct environment for better embryo culture
• AB DigiHealth – AI-powered NGS analytics for maternal-fetal health diagnostics
• Sofiva Genomics (6615.TWO) – Comprehensive genetic testing services for reproductive health
• GGA Corp. (4160.TWO) – Genetic testing solutions for embryos, newborns, and adults

 
How is Taiwan redefining the future of reproductive medicine?
Read the full analysis

編輯推薦

• 「篩精×選卵×測胚胎」 次世代解方
• 臺灣生殖醫學產業待推進！「新技術、國際醫療、半導體」三利基、國際行銷、研發環境」兩挑戰
• 基因檢測/AI提升懷孕率 老化、習慣性流產仍待解【會員限定，登入可讀，免費註冊】
• 臺灣生育率全球倒數第一！ 不孕症治療創新趨勢
• AI選卵 助攻試管嬰兒療程新招 ！？